Renal cancer : current status and innovations / / edited by Christopher Anderson and Mehran Afshar

• Pubblicazione: Cham, Switzerland : , : Springer, , [2022]; ©2022
• Descrizione fisica: 1 online resource (267 pages)
• Disciplina: 616.99461
• Soggetto topico: Kidneys - Cancer - Diagnosis
• Persona (resp. second.): AndersonChristopher <1966->; AfsharMehran
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Intro -- Contents -- Introduction -- References -- Epidemiology and Screening in RCC -- Epidemiology -- Risk Factors -- Rationale for Screening -- Screening Test -- The Screening Population -- Screening Implementation and Public Acceptability -- Current Nuances -- References -- Hereditary Renal Cancer Predisposition Syndromes -- Von Hippel Lindau (VHL) Disease -- Clinicopathological Hallmarks -- Genetics and Molecular Pathogenesis -- Clinical Management and Therapeutic Approaches -- Germline MET Variants: Hereditary Papillary Renal Cell Carcinoma (HPRC) Syndrome -- Clinicopathological Hallmarks -- Genetics and Molecular Pathogenesis -- Clinical Management and Therapeutic Approaches -- Herediatry Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome -- Clinicopathological Hallmarks -- Germline Genetics and Molecular Pathogenesis -- Clinical Management and Therapeutic Considerations -- Succinate Dehydrogenase Deficient RCC -- Clinicopathological Hallmarks -- Genetics and Molecular Pathogenesis -- Clinical Management and Therapeutic Considerations -- Disruption of the TCA Cycle: Oncometabolites in RCC -- Birt-Hogg-Dube (BHD) Syndrome -- Clinicopathological Hallmarks -- Genetics and Molecular Pathogenesis -- Clinical Management and Therapeutic Approaches -- BRCA1-Associated Protein (BAP1) Tumour Predisposition Syndrome -- Clinicopathological Hallmarks -- Genomics and Molecular Pathogenesis -- Clinical Management and Therapeutic Approaches -- Tuberous Sclerosis Complex (TSC) Syndrome -- Clinicopathological Hallmarks -- Genetics, Molecular Pathogenesis and Morphology -- Clinical Management and Therapeutic Approaches -- Cowden Syndrome -- Clinicopathological Hallmarks -- Germline Genetics and Molecularpathogenesis -- Conclusions -- References -- Imaging in Renal Cancer -- Introduction -- Detection and Characterization -- Cystic Renal Lesions. ; Solid Renal Masses -- Anatomic and Topographic Features -- Staging -- Current Nuances -- References -- Pathological Classification and Biomarkers -- Introduction -- WHO Classification of Renal Cell Carcinoma -- Clear Cell Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Papillary Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Chromophobe Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- MiT Family Translocation-Associated Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Renal Medullary Carcinoma -- Morphology -- Immunohistochemical Profile -- Renal Collecting Duct Carcinoma -- Morphology -- Immunohistochemical Profile -- Clear Cell Papillary Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Mucinous Tubular and Spindle Cell Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Multilocular Cystic Renal Cell Neoplasm of Low Malignant Potential -- Morphology -- Immunohistochemical Profile -- Tubulocystic Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Acquired Cystic Disease Associated Renal Cell Carcinoma -- Morphology -- Immunohistochemical Profile -- Unclassified Renal Cell Carcinoma -- Immunohistochemical Profile -- Hereditary Renal Cancer Syndromes -- Emerging Renal Cancer Types -- TFEB-Amplified RCC -- Eosinophilic Solid and Cystic RCC -- Biomarkers in RCC -- Conclusion -- References -- Biomarkers, Early Detection and Biomarker Based Treatment of Renal Cancer -- Introduction -- Biomarkers and Imaging Modalities -- Serum Biomarkers -- VEGF -- Interleukin 6 -- LDH and mTOR -- Non-CAF Prognostic Serum Biomarkers -- Urinary Biomarkers -- ctDNA (Liquid Biopsy) -- Tissue Based Biomarkers -- Immunohistochemistry -- Genetic Based Biomarkers -- VHL Gene -- Other Genetic Based RCCs -- Imaging Modalities for Early Detection. ; MRI -- PET -- Newer Imaging Platforms -- Conclusions -- References -- The Role of Biopsy in RCC -- Introduction -- Why Perform Renal Mass Biopsy -- Current Trends -- How to Perform RMB -- Controversies in Renal Biopsy -- How RMB Can Change Clinical Management -- Conclusions -- References -- Active Surveillance in Renal Cancer -- Introduction -- Active Surveillance -- Patient Selection -- Role of Renal Tumour Biopsy -- Imaging Surveillance -- Parameters to Monitor in AS -- Risks and Benefits of AS -- What Do the Guidelines State? -- Conclusion -- References -- The Role of Ablative Therapies in Renal Cancer -- Introduction -- Indications for Ablation Treatment -- Technical Considerations for Treatment -- Treatment Types -- Radiofrequency Ablation (RFA) -- Microwave Ablation -- Thermal Ablative Technique that Utilize Cooling -- Cryoablation -- Non Thermal Ablative Therapies -- Irreversible Electroporation -- Outcomes -- Oncological Outcomes -- Renal Function and Complication Rates -- Nuances -- Treatment Planning -- New Technology -- Conclusion -- References -- Open Radical Nephrectomy -- Introduction -- Indications -- Pre-Operative Embolisation of the Kidney -- The Incision -- The Flank Approach -- Thoraco-Abdominal Approach -- Anterior Subcostal Approach -- Lexus or L-Shaped Incision -- Radical Nephrectomy -- Surgery for Kidney Tumours with IVC Thrombus -- Pre-Operative Imaging -- Further Pre-Operative Considerations -- Pulmonary Emboli -- Budd-Chiari Syndrome -- Anaemia -- Resection -- Mayo Level 0 -- Mayo Level 1 -- Mayo Level 2 -- Mayo Level 3 -- Mayo Level 4 -- IVC Ligation and Grafting -- References -- Radical Nephrectomy for Renal Cell Carcinoma: Non-robotic Minimally Invasive Approaches -- Introduction -- Contraindications -- Approaches -- Transperitoneal -- Retroperitoneal -- Hand-Assisted -- Single-Site. ; Natural Orifice Transluminal Endoscopic Surgery (NOTES) -- Current Nuances -- References -- Radical Nephrectomy: Role of Robotic Assisted Approach -- Introduction -- Indications for Radical Nephrectomy -- Training -- Large Renal Masses -- Lymph Node Dissection -- Caval Thrombectomy -- Other Challenges: Pushing the Boundaries of Robotic Nephrectomy -- Controversies in RALN -- Conclusion -- References -- Contemporary Role of Open Nephron Sparing Surgery -- Introduction -- Indications for NSS -- Surgical techniques in NSS -- Morbidity -- Outcome -- Conclusions -- References -- Retroperitoneal Robotic Partial Nephrectomy -- Introduction -- Inception -- Current Myths and Misconceptions -- Retroperitoneal Robotically Assisted Partial Nephrectomy: Technique and Tips -- Patient Positioning -- Creating the Retroperitoneal Space -- Port Placement -- Docking -- Initial Landmarks -- Hilar Dissection -- Tumour Identification -- Hilar Clamping -- Tumour Excision -- Renorrhaphy -- Hilar Unclamping and Tumour Retrieval -- Post-Operative Care -- Is RP-RAPN Safe, Efficacious and Affordable? -- Perioperative Outcomes -- Oncological and Functional Outcomes -- Cost Implications -- Challenging the Current Consensus -- Future Trends in RP-RAPN -- References -- Transperitoneal Robotic Partial Nephrectomy -- Introduction -- Nephrometry Scoring of Renal Anatomy and Tumour Complexity -- Selection of the Surgical RAPN Approaches -- Intraoperative Localization of Renal Lesions -- Clamping Technique -- Tumour Excision and Renorrhaphy -- Renorrhaphy Techniques -- References -- Lymph Node Dissection in Renal Cancer and Upper Tract Urothelial Cancer -- Lymph Node Dissection in Renal Cell Carcinoma -- Introduction -- Guidelines -- Evidence -- Anatomical Considerations and Surgical Templates -- Salvage Lymph Node Dissection -- Imaging -- Molecular and Genetic Markers. ; Lymph Node Dissection in Upper Tract Urothelial Carcinoma -- References -- Metastatic Renal Cancer: Systemic Therapy -- Background -- Introduction -- Tyrosine Kinase Inhibitors in the First Line Setting -- Tyrosine Kinase Inhibitors Beyond the First Line Setting -- Immune Checkpoint Inhibitors -- Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations -- Discussion -- Conclusion -- References -- Metastatic Renal Cancer: Radiotherapy -- Introduction -- Conventional Palliative Radiotherapy -- Stereotactic Radiotherapy -- References -- Metastatic Tumours: Cytoreductive Nephrectomy -- Introduction -- History -- CRN Alone -- Cytoreductive Nephrectomy in Combination with Systemic Therapy -- Tyrosine Kinase Inhibitor (TKI's) ERA -- The CARMENA Trial -- SURTIME -- Active Surveillance of Metastatic Kidney Cancer -- Impact of the Immuno-Oncology (IO) Era -- Selecting the Candidate for Cytoreductive Nephrectomy -- Other Indications for Cytoreductive Nephrectomy -- Future Work -- Conclusion -- References -- Urothelial Cell Carcinoma of the Kidney and Other Non-clear Cell Renal Cell Carcinomas -- Urothelial Cell Carcinoma of the Kidney -- Non-clear Cell Renal Cell Carcinomas -- Introduction -- Multilocular Cystic Renal Neoplasm of Low Malignant Potential (MCRCC) -- Papillary RCC (pRCC) -- Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated RCC (HLRCC) -- Chromophobe Renal Cell Carcinoma (ChRCC) -- Collecting Duct Carcinoma (CDC) -- Renal Medullary Carcinoma (RMC) -- MiT (Microphthalmia-Associated Transcription Factor) Family Translocation Renal Cell Carcinomas -- Succinate Dehydrogenase-Deficient Renal Cell Carcinoma -- Mucinous Tubular and Spindle Cell Carcinoma (MTSRCC) -- Tubulocystic Renal Cell Carcinoma (TCRCC) -- Acquired Cystic Disease-Associated Renal Cell Carcinoma (ACD-RCC) -- Clear Cell Papillary Renal Cell Carcinoma (CCP-RCC). ; Renal Cell Carcinoma, Unclassified.
• Titolo autorizzato: Renal Cancer
• ISBN: 3-030-84756-X
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910559390903321
• Lo trovi qui: Univ. Federico II